Company Overview and News


Add EIGR
to your dashboard

Headline News

EIGR / Eiger BioPharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-09 fintel.io
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has 47 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,832,729 shares. Largest shareholders include Vivo Capital, LLC, Interwest Venture Management Co, Prosight Management, LP, Sphera Funds Management Ltd., and Sabby Management, Llc. (7-1)

CLDN / Celladon Corporation - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-01 fintel.io
Celladon Corporation (NASDAQ:CLDN) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,787,091 shares. Largest shareholders include Vivo Ventures VI, LLC. (10-0)

7 Speculative Analyst Stock Picks With Huge Upside Targets

2017-10-28 247wallst
The Dow Jones Industrial Average, the S&P 500 and the Nasdaq have again crossed into new all-time highs. The week of October 27 was rocked higher with many solid earnings reports out of the new darlings of Wall Street, and even the old tech names enjoyed their day in the sun. In case you haven’t gotten the memo, there is a raging bull market going on. While many investors are worrying about the next big market panic, the trend that is now well over five years old is that investors keep finding new reasons to buy stocks after every major sell-off. (27-5)

10 Speculative Analyst Stocks With Huge Potential Upside

2017-10-21 247wallst
The Dow blew through 23,000 for the first time during the week of October 20, 2017, and it was coincidentally 30 years to the day after the 1987 stock market crash. Stronger post-hurricane economic numbers, stronger earnings, a likely budget passage and probable tax cuts were all driving forces this past week. With the bull market over eight and a half years old, some investors might be thinking it’s time to bail or that the elusive huge correction may come up. (105-3)

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

2017-09-18 prnewswire
PALO ALTO, Calif., Sept. 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh's clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, across multiple therapeutic areas including oncology, infectious diseases, inflammation and rare diseases. (42-0)

Sabby Management, Llc discloses 6.15% ownership in BIOA / BioAmber Inc. - Fintel.io

2017-09-12 fintel.io
September 12, 2017 - Sabby Management, Llc has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,205,343 shares of BioAmber Inc. (NYSE:BIOA). This represents 6.15 percent ownership of the company. (0-8)

Sabby Management, Llc discloses 7.40% ownership in CVM / CEL-SCI Corp. - Fintel.io

2017-08-23 fintel.io
August 23, 2017 - Sabby Management, Llc has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 875,000 shares of CEL-SCI Corp. (AMEX:CVM). This represents 7.4 percent ownership of the company. In their previous filing dated January 10, 2017, Sabby Management, Llc had reported owning 9,417,348 shares, indicating a decrease of -90.71 percent. (0-1)

Sphera Funds Management Ltd. discloses 5.35% ownership in EIGR / Eiger BioPharmaceuticals, Inc. - Fintel.io

2017-08-22 fintel.io
August 22, 2017 - Sphera Funds Management Ltd. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 447,609 shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR). This represents 5.35 percent ownership of the company. (0-1)

Top Analyst Upgrades and Downgrades: CenterPoint, NetApp, NiSource, Nvidia, Orbital ATK, Weyerhaeuser and More

2017-08-14 247wallst
Stocks were indicated to open strong on Monday, with the Dow up almost 100 points and the S&P 500 up about 13 points. Even with the market being just under all-time highs, the one trend that dominated more than half of the eight-year bull market is that investors have managed to keep finding new reasons to buy stocks after every sell-off. Those same investors are also searching for new investing and trading ideas.

BlackRock's (BLK) Q2 Earnings Miss Estimates, Revenues Rise

2017-07-17 zacks
Have you been eager to see how BlackRock, Inc. (BLK - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based investment management company’s earnings release this morning: An Earnings Miss BlackRock came out with adjusted earnings per share of $5.24, beating the Zacks Consensus Estimate of $5.39. Lower-than-expected earnings were primarily due to higher expenses.

Amira Nature Foods (ANFI) Catches Eye: Stock Gains 7.9%

2017-07-17 zacks
Amira Nature Foods Ltd. (ANFI - Free Report) was a big mover last session, as its shares rose over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 31% in the past one-month time frame.

Top Analyst Upgrades and Downgrades: Alphabet, Boeing, CyberArk, Eiger BioPharma, Hewlett Packard Enterprise, Snap, Ulta Beauty, Walmart and More

2017-07-14 247wallst
Stocks were up again on Thursday but were looking for direction on Friday. The indexes are all within striking distance of all-time highs, and the bull market is more than eight years old. Investors keep changing their reasoning behind why, but the prevailing trend is that every big sell-off has been met with serious buying. It also turns out that investors are searching for new investing and trading ideas.

BRIEF-Eiger BioPharma announces sale of non-strategic assets to Theragene Pharma

2017-06-29 reuters
* Eiger BioPharmaceuticals Inc - financial terms of agreement include a total upfront of $3.1 million in payments from Theragene to Eiger

CUSIP: 28249U105